These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 20854803

  • 1. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 2. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR, Sullivan SK, Schwarz DA, Ling N, Vale WW, Crowe PD, Grigoriadis DE.
    Biochemistry; 2004 Apr 06; 43(13):3996-4011. PubMed ID: 15049707
    [Abstract] [Full Text] [Related]

  • 3. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep 06; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 4. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM, Wille S.
    Regul Pept; 2004 May 15; 118(3):165-73. PubMed ID: 15003833
    [Abstract] [Full Text] [Related]

  • 5. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 15; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 6. Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors.
    Zhang G, Huang N, Li YW, Qi X, Marshall AP, Yan XX, Hill G, Rominger C, Prakash SR, Bakthavatchalam R, Rominger DH, Gilligan PJ, Zaczek R.
    J Pharmacol Exp Ther; 2003 Apr 15; 305(1):57-69. PubMed ID: 12649353
    [Abstract] [Full Text] [Related]

  • 7. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 15; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 8. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, Grigoriadis DE.
    Mol Pharmacol; 2008 May 15; 73(5):1371-80. PubMed ID: 18239030
    [Abstract] [Full Text] [Related]

  • 9. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
    Klose J, Fechner K, Beyermann M, Krause E, Wendt N, Bienert M, Rudolph R, Rothemund S.
    Biochemistry; 2005 Feb 08; 44(5):1614-23. PubMed ID: 15683245
    [Abstract] [Full Text] [Related]

  • 10. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH, Sutton SW, Cervini LA, Rivier JE, Vale WW.
    J Pharmacol Exp Ther; 1999 Feb 08; 288(2):729-34. PubMed ID: 9918582
    [Abstract] [Full Text] [Related]

  • 11. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
    Lawrence AJ, Krstew EV, Dautzenberg FM, Rühmann A.
    Br J Pharmacol; 2002 Jul 08; 136(6):896-904. PubMed ID: 12110614
    [Abstract] [Full Text] [Related]

  • 12. 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.
    Higelin J, Py-Lang G, Paternoster C, Ellis GJ, Patel A, Dautzenberg FM.
    Neuropharmacology; 2001 Jul 08; 40(1):114-22. PubMed ID: 11077077
    [Abstract] [Full Text] [Related]

  • 13. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor.
    Xiong Y, Xie LY, Abou-Samra AB.
    Endocrinology; 1995 May 08; 136(5):1828-34. PubMed ID: 7720627
    [Abstract] [Full Text] [Related]

  • 14. New class of corticotropin-releasing factor (CRF) antagonists: small peptides having high binding affinity for CRF receptor.
    Yamada Y, Mizutani K, Mizusawa Y, Hantani Y, Tanaka M, Tanaka Y, Tomimoto M, Sugawara M, Imai N, Yamada H, Okajima N, Haruta J.
    J Med Chem; 2004 Feb 26; 47(5):1075-8. PubMed ID: 14971886
    [Abstract] [Full Text] [Related]

  • 15. Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor.
    Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE.
    J Pharmacol Exp Ther; 2012 May 26; 341(2):518-31. PubMed ID: 22357972
    [Abstract] [Full Text] [Related]

  • 16. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.
    Ardati A, Goetschy V, Gottowick J, Henriot S, Valdenaire O, Deuschle U, Kilpatrick GJ.
    Neuropharmacology; 1999 Mar 26; 38(3):441-8. PubMed ID: 10219982
    [Abstract] [Full Text] [Related]

  • 17. Ligand requirements of the human corticotropin-releasing factor-binding protein.
    Sutton SW, Behan DP, Lahrichi SL, Kaiser R, Corrigan A, Lowry P, Potter E, Perrin MH, Rivier J, Vale WW.
    Endocrinology; 1995 Mar 26; 136(3):1097-102. PubMed ID: 7867564
    [Abstract] [Full Text] [Related]

  • 18. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
    Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL.
    J Neurochem; 1999 Aug 26; 73(2):821-9. PubMed ID: 10428081
    [Abstract] [Full Text] [Related]

  • 19. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
    Behan DP, De Souza EB, Lowry PJ, Potter E, Sawchenko P, Vale WW.
    Front Neuroendocrinol; 1995 Oct 26; 16(4):362-82. PubMed ID: 8557170
    [Abstract] [Full Text] [Related]

  • 20. 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophore-based drug design.
    Ye Y, Liao Q, Wei J, Gao Q.
    Neurochem Int; 2010 Jan 26; 56(1):107-17. PubMed ID: 19782115
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.